Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue  by Mancuso, Andrea et al.
[3] Thalheimer U, Burrhougs AK. To close the stable door before the horse has
bolted. J Hepatol 2014;60:678–679.
[4] Bucsics T, Schwabl P, Soucek K, Mandorfer M, Ferlitsch A, Peck-Radosavljevic
M, et al. Is acute kidney injury stage 1 (AKI 1) according to modiﬁed AKIN
criteria associated with higher mortality in cirrhotic patients with ascites?
Hepatology 2013;58:864A, [abstract].
[5] Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis.
Gut 2013;62:131–137.
Salvatore Piano
Filippo Morando
Paolo Angeli⇑
Department of Medicine (DIMED),
University of Padova, Italy⇑Corresponding author.
E-mail address: pangeli@unipd.it
JOURNAL OF HEPATOLOGY
OpSorafenib efﬁcacy for treatment of HCC recurrence after liver
transplantation is an open issueReferences
[1] Sposito C, Mariani L, Germini A, Reyes MF, Bongini M, Grossi G, et al.
Comparative efﬁcacy of sorafenib vs. best supportive care in recurrent
hepatocellular carcinoma after liver transplantation: a case-control study. J
Hepatol 2013;59:59–66.
[2] Toso C, Mentha G, Majno P. Integrating sorafenib into an algorithm for the
management of post-transplant hepatocellular carcinoma recurrence. J
Hepatol 2013;59:3–5.
[3] Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, Lampis A, et al.
Personalized molecular targeted therapy in advanced, recurrent hepatocel-
lular carcinoma after liver transplantation: a proof of principle. J Hepatol
2010;52:771–775.
[4] Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, et al.
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect
of combined sorafenib and rapamycin in vivo. J Hepatol 2009;51:725–733.
[5] Gangadhar TC, Cohen EE, Wu K, Janisch L, Geary D, Kocherginsky M, et al.
Two drug interaction studies of sirolimus in combination with sorafenib or
sunitinib in patients with advanced malignancies. Clin Cancer Res
2011;17:1956–1963.
[6] Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Vigano R, Cordone G, et al.
Adverse events affect sorafenib efﬁcacy in patients with recurrent hepato-
cellular carcinoma after liver transplantation: experience at a single center
and review of the literature. Eur J Gastroenterol Hepatol 2013;25:180–186.
[7] Staufer K, Fischer L, Seegers B, Vettorazzi E, Nashan B, Sterneck M. High
toxicity of sorafenib for recurrent hepatocellular carcinoma after liver
transplantation. Transpl Int 2012;25:1158–1164.
[8] Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Duber C,
et al. Sorafenib for recurrence of hepatocellular carcinoma after liver
transplantation. Dig Liver Dis 2012;44:432–437.
[9] Piguet AC, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, Radojevic V,
et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic
model of hepatocellular carcinoma. Mol Cancer Ther 2011;10:1007–1017.
[10] Mancuso A, Airoldi A, Vigano R, Pinzello G. Fatal gastric bleeding during
sorafenib treatment for hepatocellular carcinoma recurrence after liver
transplantation. Dig Liver Dis 2011;43:754.
Andrea Mancuso⇑
Chiara Mazzarelli
Giovanni Perricone
Claudio Zavaglia
Epatologia e Gastroenterologia, Ospedale Niguarda Cà Granda,
Piazza Ospedale Maggiore 3, 20162 Milano, Italy⇑Corresponding author. Tel.: +39 0264444435;
fax: +39 0264442895.
E-mail address: mancandrea@libero.itTo the Editor:
We read with interest the case-control study on sorafenib treat-
ment for hepatocellular carcinoma (HCC) recurrence after liver
transplantation (LT) recently published in the Journal of Hepatol-
ogy [1]. The study reports the consecutive experience on 15
patients with no otherwise treatable HCC recurrence after LT,
who underwent treatment with Sorafenib. Outcome was com-
pared with those of 24 historical consecutive controls. Overall,
an outcome beneﬁt statistically attributed to sorafenib was
reported for the former group. Despite some strong bias, namely
the case-control design of the study and the different immuno-
suppressive regimes between the two groups, possibly affecting
HCC outcome, the take home message of both the study and
the accompanying Editorial seems to be that since sorafenib is
already of proven efﬁcacy for HCC recurrence treatment after
LT, its indication should be added to the next guidelines [1,2].
However, overall evidence of sorafenib efﬁcacy for HCC recur-
rence after LT is actually weak.
Previous studies reported non homogeneous outcome after
treatment of HCC recurrence after LT using sorafenib. In fact,
despite the optimist results of some studies, more than one cen-
tre reported negative experiences [3–9].
In disagreement with the ﬁndings of the present study, we
and others previously reported signiﬁcant toxicity of sorafenib
in the post-transplant setting [6,7]. In particular, one group
reported grade 3–4 adverse events in 92% of 13 patients, resulting
in sorafenib discontinuation in 77% [6]. Our experience on 15
consecutive patients, as partially reported on 11, describes a high
rate of intolerance or side-effects, causing drug discontinuation in
36% of 11 patients [7]. Moreover, one patient died because of
massive gastrointestinal bleeding, as previously fully described
[10], suggesting the concern that everolimus and sorafenib inter-
action could facilitate gastrointestinal bleeding [3].
In conclusion, we believe that there is not yet enough evi-
dence to draw any deﬁnite conclusion on indication of sorafenib
for HCC recurrence treatment after LT. Albeit difﬁcult to perform,
a multicenter prospective sorafenib vs. placebo controlled trial
should be advocated.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.Journal of Hepatology 2014 vol. 60 j 676–683 681
en access under CC BY-NC-ND license.
